With phase II trials for Parkinson's disease completed, inosine will continue to phase III trials. Earlier trials suggested that patients with the highest serum urate levels had slower progression of Parkinson's symptoms. The trial uses inosine to raise urate levels in those with levels lower than the population mean (6 mg/dL).
With phase II trials for Parkinson's disease completed inosine will continue to phase III trials Earlier trials suggested that patients with the highest serum urate levels had slower progression of Parkinson's symptoms The trial uses inosine to raise urate levels in those with levels lower than the population mean (6 mg/dL)